Kucherenko, Mariya M.
Sang, Pengchao
Yao, Juquan
Gransar, Tara
Dhital, Saphala http://orcid.org/0000-0001-5566-0733
Grune, Jana
Simmons, Szandor
Michalick, Laura http://orcid.org/0000-0002-3959-5828
Wulsten, Dag
Thiele, Mario
Shomroni, Orr http://orcid.org/0000-0002-8009-2392
Hennig, Felix
Yeter, Ruhi
Solowjowa, Natalia
Salinas, Gabriela http://orcid.org/0000-0001-8269-2669
Duda, Georg N. http://orcid.org/0000-0001-7605-3908
Falk, Volkmar http://orcid.org/0000-0002-7911-8620
Vyavahare, Naren R.
Kuebler, Wolfgang M. http://orcid.org/0000-0003-4100-2961
Knosalla, Christoph http://orcid.org/0000-0002-8127-5019
Article History
Received: 14 September 2021
Accepted: 4 July 2023
First Online: 21 July 2023
Competing interests
: N.R.V. holds significant equity in Elastrin Therapeutics Inc. which has licensed elastin-targeted nanoparticle therapy for cardiovascular and pulmonary conditions. V.F. receives remuneration, consultancy fees, and/or travel support outside the submitted work from Abbott GmbH & Co. KG, Novartis Pharma GmbH, Medtronic GmbH, Biotronic SE &Co., Boston Scientific, Edwards Lifesciences, Berlin Heart, JOTEC GmbH, Zurich Heart. M.M.K., W.M.K., and C.K. have filed a European Patent application (P30606WO) on “Pentagalloyl glucose (PGG) for use in the treatment of pulmonary hypertension”. The remaining authors declare no competing interests.